Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Profit After Tax (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Profit After Tax data on record, last reported at -$25.4 million in Q3 2025.

  • For Q3 2025, Profit After Tax fell 139.79% year-over-year to -$25.4 million; the TTM value through Sep 2025 reached -$51.4 million, down 62.67%, while the annual FY2024 figure was -$21.8 million, 26.89% up from the prior year.
  • Profit After Tax reached -$25.4 million in Q3 2025 per MBRX's latest filing, down from -$17.8 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$2.3 million in Q4 2024 and bottomed at -$25.4 million in Q3 2025.
  • Average Profit After Tax over 5 years is -$7.8 million, with a median of -$6.4 million recorded in 2024.
  • Peak YoY movement for Profit After Tax: soared 77.61% in 2024, then tumbled 312.34% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$2.8 million in 2021, then crashed by 139.05% to -$6.8 million in 2022, then tumbled by 51.68% to -$10.3 million in 2023, then skyrocketed by 77.61% to -$2.3 million in 2024, then crashed by 1004.78% to -$25.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$25.4 million in Q3 2025, -$17.8 million in Q2 2025, and -$5.9 million in Q1 2025.